The accompanying accounting policies and explanatory notes form an integral part of the financial statements. Consolidated cash flow statement For the financial year ended 31 December 2023 Note 2023 2022 Rp million Rp million Cash flows from investing activities Additions to property, plant and equipment (977,888) (1,239,002) Additions to right-of-use assets 15 – (1,170) Additions to biological assets (280,062) (237,362) (Increase)/decrease in plasma receivables 32(a) (84,129) 13,294 Proceeds from disposal of property, plant and equipment 14 34,598 30,333 Advances for projects and purchases of fixed assets (8,576) (13,175) Dividend received from a joint venture 63,712 127,703 Additional investment in a joint venture 21 – (83,447) Additional investment in associate companies – (62,794) Net cash flows used in investing activities (1,252,345) (1,465,620) Cash flows from financing activities Proceeds from interest-bearing loans and borrowings 5,819,000 6,149,714 Repayment of interest-bearing loans and borrowings (7,146,863) (7,408,151) Dividend payments by subsidiaries to non-controlling interests (207,664) (194,315) Dividend payment to Company’s shareholders (123,561) (117,815) Payment of lease liabilities 15 (57,258) (57,002) Net cash flows used in financing activities (1,716,346) (1,627,569) Net increase in cash and cash equivalents 833,633 538,678 Effect of changes in exchange rates on cash and cash equivalents (30,474) 120,049 Cash and cash equivalents at the beginning of the financial year 4,422,371 3,763,644 Cash and cash equivalents at the end of the financial year 25 5,225,530 4,422,371 69 GROUP OVERVIEW OPERATION AND FINANCIAL REVIEW SUSTAINABILITY & GOVERNANCE FINANCIALS OTHER INFORMATION Annual Report 2023
RkJQdWJsaXNoZXIy NTkwNzg=